Literature DB >> 14664765

Myasthenic Crisis.

Jawad F. Kirmani1, Abutaher M. Yahia, Adnan I. Qureshi.   

Abstract

Myasthenia gravis is the most common disorder of the neuromuscular junction. Myasthenia crisis, defined as respiratory failure requiring mechanical ventilation in myasthenia gravis, is a common life-threatening complication that occurs in approximately 15% to 20% of patients with myasthenia gravis. The advent of effective mechanical ventilation, specialized neurointensive care units, and the widespread use of immunotherapies have substantially altered the prognosis of myasthenic crisis. The authors recommend more liberal intubation of patients with myasthenia gravis crisis; early intubation and mechanical ventilation is perhaps the most important step in the management of myasthenia gravis crisis. The authors favor an orotracheal approach for intubation, and placement of small bore duodenal tubes that may help decrease the risk of aspiration and may be more comfortable than regular nasogastric tubes for the patient. Plasma exchange is more effective than intravenous immunoglobulin in the treatment of myasthenia gravis involving respiratory failure. A randomized trial is required to confirm the superior efficacy of plasma exchange compared with intravenous immunoglobulin. In the acute setting, the role of immunosuppression and intravenous or intramuscular pyridostigmine remains limited and at times controversial. The therapy should be tailored on an individual basis using the best clinical judgment.

Entities:  

Year:  2004        PMID: 14664765     DOI: 10.1007/s11940-004-0034-3

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  15 in total

1.  Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

Authors:  A I Qureshi; M A Choudhry; M S Akbar; Y Mohammad; H C Chua; A M Yahia; J A Ulatowski; D A Krendel; R T Leshner
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

2.  Treatment of myasthenia gravis: A call to arms.

Authors:  J T Kissel; G M Franklin
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

3.  Therapy in neuromuscular disease.

Authors:  D S Younger; N Raksadawan
Journal:  Neurol Clin       Date:  2001-02       Impact factor: 3.806

Review 4.  How to handle myasthenic crisis. Essential steps in patient care.

Authors:  R S Bedlack; D B Sanders
Journal:  Postgrad Med       Date:  2000-04       Impact factor: 3.840

5.  Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.

Authors:  P Gajdos; S Chevret; B Clair; C Tranchant; C Chastang
Journal:  Ann Neurol       Date:  1997-06       Impact factor: 10.422

6.  Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin.

Authors:  R B Stricker; B J Kwiatkowska; J A Habis; D D Kiprov
Journal:  Arch Neurol       Date:  1993-08

7.  The history of myasthenia gravis.

Authors:  R M Pascuzzi
Journal:  Neurol Clin       Date:  1994-05       Impact factor: 3.806

8.  Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation.

Authors:  C E Thomas; S A Mayer; Y Gungor; R Swarup; E A Webster; I Chang; T H Brannagan; M E Fink; L P Rowland
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

9.  Aspects of the natural history of myasthenia gravis: crisis and death.

Authors:  M S Cohen; D Younger
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

10.  The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis.

Authors:  P Rieder; M Louis; P Jolliet; J C Chevrolet
Journal:  Intensive Care Med       Date:  1995-08       Impact factor: 17.440

View more
  8 in total

1.  Risk of extubation failure in patients with myasthenic crisis.

Authors:  Alejandro A Rabinstein; Nils Mueller-Kronast
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  Myasthenic crisis.

Authors:  Linda C Wendell; Joshua M Levine
Journal:  Neurohospitalist       Date:  2011-01

3.  Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years.

Authors:  X Huang; W B Liu; L N Men; H Y Feng; Y Li; C M Luo; L Qiu
Journal:  Neurol Sci       Date:  2012-07-18       Impact factor: 3.307

4.  Myasthenia gravis treated in the neurology intensive care unit: a 14-year single-centre experience.

Authors:  Mirjana Zdraljevic; Stojan Peric; Marta Jeremic; Dragana Lavrnic; Ivana Basta; Ljiljana Hajdukovic; Dejana R Jovanovic; Ivana Berisavac
Journal:  Neurol Sci       Date:  2022-09-09       Impact factor: 3.830

5.  Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development.

Authors:  Anne Taraldsen Heldal; Geir Egil Eide; Fredrik Romi; Jone Furlund Owe; Nils Erik Gilhus
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

6.  Predictors of extubation outcomes following myasthenic crisis.

Authors:  Zhenguo Liu; Shiyuan Yao; Qian Zhou; Zhensheng Deng; Jianyong Zou; Huiyu Feng; Hua Zhu; Chao Cheng
Journal:  J Int Med Res       Date:  2016-11-18       Impact factor: 1.671

7.  In-depth peripheral CD4+ T profile correlates with myasthenic crisis.

Authors:  Xiao Huan; Sushan Luo; Huahua Zhong; Xueying Zheng; Jie Song; Lei Zhou; Jun Lu; Ying Wang; Yafang Xu; Jianying Xi; Zhangyu Zou; Sheng Chen; Chongbo Zhao
Journal:  Ann Clin Transl Neurol       Date:  2021-02-22       Impact factor: 4.511

Review 8.  Acetylcholinesterase Inhibitors in Myasthenic Crisis: A Systematic Review of Observational Studies.

Authors:  Mario B Prado; Karen Joy Adiao
Journal:  Neurocrit Care       Date:  2021-07-22       Impact factor: 3.210

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.